---
title: "What will the FDA's decision be on Ivonescimab by Summit Therapeutics in 2026?"
canonical_url: https://betcrypto.now/events/what-will-the-fdas-decision-be-on-ivonescimab-by-summit-therapeutics-in-2026
status: live
trading_closes_at: 2027-01-01T04:59:00+00:00
total_volume_usd: 8928.66
venues: ["Kalshi"]
categories: ["Markets"]
prices_as_of: 2026-10-09T07:19:32+00:00
publisher: BetCrypto
data_api: https://betcrypto.now/api/v1/events/what-will-the-fdas-decision-be-on-ivonescimab-by-summit-therapeutics-in-2026
---

# What will the FDA's decision be on Ivonescimab by Summit Therapeutics in 2026?

Live · $8,929 traded · listed on Kalshi

## About

If the FDA's decision on Ivonescimab by Summit Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.

Ivonescimab (also called AK112 or SMT112) is a bispecific antibody — think of it as a single engineered drug molecule that carries two different "hooks" instead of one, allowing it to grab and block two disease-promoting proteins at the same time. It was developed by Akeso and is being commercialized outside China by Summit Therapeutics. By simultaneously neutralizing both targets, ivonescimab is designed to slow cancer growth more effectively than drugs that block only one pathway at a time.

This market and these products have not been endorsed by any aforementioned brands or its affiliates. Any references to the brand, or any associated marks are descriptive only and do not indicate an endorsement of this product or any affiliation between the brand or its affiliates and Kalshi.

_From Kalshi's listing._

## Main market

| Outcome | Probability | Cheapest | Kalshi |
|---|---|---|---|
| Yes | 50% | 53¢ on Kalshi | 53¢ |
| No | 50% | 53¢ on Kalshi | 53¢ |

## Open on a venue

- [Kalshi](https://betcrypto.now/go/e/2223?via=md)

---

Probability is the cross-venue consensus (book midpoints, 0–100%). Venue columns are what buying costs there (the ask). Prices move constantly; re-check at the canonical URL or https://betcrypto.now/api/v1/events/what-will-the-fdas-decision-be-on-ivonescimab-by-summit-therapeutics-in-2026.

BetCrypto is an odds-comparison and information service. It accepts no wagers and gives no betting or financial advice; prediction-market availability depends on where you live.